Olivier Gout

Summary

Affiliation: rue Manin
Country: France

Publications

  1. pmc Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo
    Linda Zane
    CNRS UMR5239, Universite de Lyon, Oncovirologie et Biothérapies, Centre Leon Berard, 69008 Lyon, France
    Retrovirology 7:17. 2010
  2. ncbi request reprint Facial diplegia complicating a bilateral internal carotid artery dissection
    O Gout
    Departments of Neurology, Interventional Neuroradiology, Fondation Ophtalmologique A de Rothschild, Paris, France
    Stroke 30:681-6. 1999
  3. doi request reprint Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event
    O Gout
    Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild, 25 27 rue Manin, Paris 75019, France
    J Neurol Neurosurg Psychiatry 82:323-5. 2011
  4. doi request reprint Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event
    Olivier Gout
    Department of Neurology, Fondation Ophtalmologique A de Rothschild, France
    Mult Scler 17:164-72. 2011
  5. ncbi request reprint [Current treatment of multiple sclerosis]
    O Gout
    Service de Neurologie, Fondation Ophtalmologique A de Rothschild, 25 27, rue Manin, 75019 Paris, France
    Rev Med Interne 31:575-80. 2010
  6. ncbi request reprint Microangiopathy of the inner ear, retina, and brain (Susac syndrome): report of a case
    D Ayache
    Department of Ears, Nose, and Throat, Fondation Adolphe de Rothschild, Paris, France
    Arch Otolaryngol Head Neck Surg 126:82-4. 2000
  7. ncbi request reprint [Sub-cortico-frontal encephalopathy and choreic movements related to recombinant interferon-alpha 2b]
    A Moulignier
    Fondation Adolphe de Rothschild, Service de Neurologie, 25 rue Manin, 75940 Paris Cedex 19
    Rev Neurol (Paris) 158:567-72. 2002
  8. ncbi request reprint Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
    Antoine Gueguen
    Department of Neurology, Fondation Ophtalmologique A de Rothschild, Paris, France
    J Neurol Neurosurg Psychiatry 85:1038-40. 2014
  9. ncbi request reprint Immunosuppressive therapy is more effective than interferon in neuromyelitis optica
    C Papeix
    Department of Neurology, Hopital de la Salpetriere, Paris, France
    Mult Scler 13:256-9. 2007
  10. doi request reprint Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
    Christine Lebrun
    Service de Neurologie, CHU Pasteur, 06002 Nice, France
    Mult Scler 14:399-405. 2008

Collaborators

Detail Information

Publications16

  1. pmc Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo
    Linda Zane
    CNRS UMR5239, Universite de Lyon, Oncovirologie et Biothérapies, Centre Leon Berard, 69008 Lyon, France
    Retrovirology 7:17. 2010
    ..HTLV-1 expression is cancer-prone in vitro, but in vivo numerous selection forces act to maintain T cell homeostasis and are possibly involved in clonal selection...
  2. ncbi request reprint Facial diplegia complicating a bilateral internal carotid artery dissection
    O Gout
    Departments of Neurology, Interventional Neuroradiology, Fondation Ophtalmologique A de Rothschild, Paris, France
    Stroke 30:681-6. 1999
    ..We report a case of facial diplegia complicating a bilateral internal carotid artery dissection...
  3. doi request reprint Prior suggestive symptoms in one-third of patients consulting for a "first" demyelinating event
    O Gout
    Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild, 25 27 rue Manin, Paris 75019, France
    J Neurol Neurosurg Psychiatry 82:323-5. 2011
    ..To evaluate the prevalence of prior inflammatory events in patients consulting for a first inflammatory neurological event and improve early diagnosis of multiple sclerosis...
  4. doi request reprint Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event
    Olivier Gout
    Department of Neurology, Fondation Ophtalmologique A de Rothschild, France
    Mult Scler 17:164-72. 2011
    ..This study aimed to assess the value of cerebrospinal fluid (CSF) findings for predicting conversion to clinically definite multiple sclerosis (CDMS)...
  5. ncbi request reprint [Current treatment of multiple sclerosis]
    O Gout
    Service de Neurologie, Fondation Ophtalmologique A de Rothschild, 25 27, rue Manin, 75019 Paris, France
    Rev Med Interne 31:575-80. 2010
    ..Lately, in 2002, mitoxantrone was approved for aggressive relapsing-remitting MS and in 2007 the first monoclonal antibody (natalizumab) was approved for active relapsing-remitting MS...
  6. ncbi request reprint Microangiopathy of the inner ear, retina, and brain (Susac syndrome): report of a case
    D Ayache
    Department of Ears, Nose, and Throat, Fondation Adolphe de Rothschild, Paris, France
    Arch Otolaryngol Head Neck Surg 126:82-4. 2000
    ..In this article, we report a new case of Susac syndrome and discuss the diagnosis, physiopathologic characteristics, and treatment of this disease...
  7. ncbi request reprint [Sub-cortico-frontal encephalopathy and choreic movements related to recombinant interferon-alpha 2b]
    A Moulignier
    Fondation Adolphe de Rothschild, Service de Neurologie, 25 rue Manin, 75940 Paris Cedex 19
    Rev Neurol (Paris) 158:567-72. 2002
    ....
  8. ncbi request reprint Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
    Antoine Gueguen
    Department of Neurology, Fondation Ophtalmologique A de Rothschild, Paris, France
    J Neurol Neurosurg Psychiatry 85:1038-40. 2014
    ..To characterise recurrence of multiple sclerosis (MS) inflammatory activity during the year following natalizumab (NTZ) cessation...
  9. ncbi request reprint Immunosuppressive therapy is more effective than interferon in neuromyelitis optica
    C Papeix
    Department of Neurology, Hopital de la Salpetriere, Paris, France
    Mult Scler 13:256-9. 2007
    ..The probability of relapse was significantly lower in the IS Group (P =0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants...
  10. doi request reprint Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
    Christine Lebrun
    Service de Neurologie, CHU Pasteur, 06002 Nice, France
    Mult Scler 14:399-405. 2008
    ..From 1 January 1995 to 30 June 2006, we collected and studied the profile of 7,418 MS patients gathered from nine French MS centers. We evaluated the incidence of cancer in a Cancer Risk In MS Cohort...
  11. doi request reprint A brainstem inflammatory lesion causing REM sleep behavior disorder and sleepwalking (parasomnia overlap disorder)
    Nadege Limousin
    Inserm UMR and Pierre and Marie Curie University, Hopital Pitie Salpetriere, APHP, Paris, France
    Sleep Med 10:1059-62. 2009
    ..The RBD and sleepwalking did not improve with clonazepam, but improved with melatonin 9 mg/d. The unilateral small lesion of the pontine tegmentum could be responsible for the parasomnia overlap disorder as in other rare lesional cases...
  12. ncbi request reprint [Susac syndrome: study of five cases]
    E Maillart
    Service de Neurologie, Fondation Ophtalmologique Adolphe de Rothschild, 25 29, rue Manin, 75940 Paris Cedex 19, France
    Rev Neurol (Paris) 165:575-82. 2009
    ..The classic clinical triad includes multiple neurologic signs (from headaches to coma), retinal branch occlusions and sensorineural hearing loss...
  13. ncbi request reprint [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year]
    S Ory
    Service de Neurologie, Hopital Pontchaillou, rue Henri Le Guilloux, 35033 Rennes Cedex, France
    Rev Neurol (Paris) 164:1028-34. 2008
    ..In an observational multicenter study, we analyzed retrospectively 30 patients with malignant form of multiple sclerosis (MS) treated with mitoxantrone the year following the first neurological event...
  14. ncbi request reprint Idiopathic acute transverse myelitis: application of the recent diagnostic criteria
    J de Seze
    Department of Neurology, University of Lille, France
    Neurology 65:1950-3. 2005
    ..In a retrospective study of 288 patients with ATM, 45 cases (15.6%) met the criteria for idiopathic ATM. The patients formed a relatively homogeneous group in terms of clinical and MRI data, but the prognosis was highly variable...
  15. ncbi request reprint Vaccinations and multiple sclerosis
    O Gout
    Federation of Neurology, Hĵpital de la Salpêtrière, Paris, France
    Neurol Sci 22:151-4. 2001
    ..Nevertheless, molecular mimicry between HB antigen(s) and one or more myelin proteins, or a non-specific activation of autoreactive lymphocytes, could constitute possible pathogenetic mechanisms for these adverse neurological events...
  16. ncbi request reprint Interferon-beta treatment in patients with childhood-onset multiple sclerosis
    Y Mikaeloff
    Department of Neuropediatrics, Saint-Vincent de Paul Hospital, Paris, France
    J Pediatr 139:443-6. 2001
    ..We present a report of the use of interferon-beta before 18 years of age in 16 patients with childhood-onset multiple sclerosis. This study demonstrated that the treatment is safe and well tolerated...